Merdad Parsey, Gilead CMO
Four months after CRL due to contaminant worries, Gilead returns to FDA for next-gen HIV drug
Just shy of four months ago, Gilead’s next-gen HIV drug candidate lenacapavir got hit with a CRL over CMC issues involving the type of vials …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
